10.73
+0.12(+1.13%)
Currency In USD
| Previous Close | 10.61 |
| Open | 10.49 |
| Day High | 10.82 |
| Day Low | 10.27 |
| 52-Week High | 13.33 |
| 52-Week Low | 5.68 |
| Volume | 314,339 |
| Average Volume | 1.12M |
| Market Cap | 633.88M |
| PE | -3.23 |
| EPS | -3.32 |
| Moving Average 50 Days | 9.9 |
| Moving Average 200 Days | 8.21 |
| Change | 0.12 |
If you invested $1000 in Cullinan Therapeutics, Inc. (CGEM) since IPO date, it would be worth $358.74 as of January 14, 2026 at a share price of $10.73. Whereas If you bought $1000 worth of Cullinan Therapeutics, Inc. (CGEM) shares 3 years ago, it would be worth $1,000 as of January 14, 2026 at a share price of $10.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended Phase 2 dose for CLN-049 pivotal registrational
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
GlobeNewswire Inc.
Dec 08, 2025 3:31 PM GMT
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31% CR/CRh rate observed at the highest target dose
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
GlobeNewswire Inc.
Dec 01, 2025 12:00 PM GMT
Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, I